Cutaneous Manifestations of Chemotherapeutic Drugs
详细信息    查看全文
Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67:1025–39. This paper is a comprehensive review of the NCI CTCAE criteria specific to dermatologic adverse events.CrossRef PubMed
3.••
Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59:524–9. This paper defined the term “toxic erythema of chemotherapy”, which allowed for consolidation of clinical terminology and improved communication between clinicians.CrossRef PubMed
4.Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol Elsevier. 2014;71:787–94.CrossRef
5.Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer. J Am Acad Dermatol Elsevier. 2014;71:203.e1–203.e12.CrossRef
6.Al-Ahwal MS. Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist. 2012;17:291–3.CrossRef PubMed PubMedCentral
7.Do JE, Kim YC. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? Clin Exp Dermatol. 2007;32:519–21.CrossRef PubMed
8.Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23:1348–53.CrossRef PubMed
9.Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz S-F, Beyeler M, et al. Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast. 2014;23:244–9.CrossRef PubMed
10.Carvalho R, Macias V, Marques-Pinto G, Afonso A, Cardoso J. Intertriginous pattern of toxic erythema of chemotherapy. Cutan Ocul Toxicol. 2011;30:309–11.CrossRef PubMed
11.Wolf R, Tüzün Y. Baboon syndrome and toxic erythema of chemotherapy: fold (intertriginous) dermatoses. Clin Dermatol. 2015;33:462–5.CrossRef PubMed
12.Murad A, Fortune A, Moloney FJ. Violaceous perivulvar nodular eruption after chemotherapy. JAMA Dermatol Am Med Assoc. 2014;150:1003–4.CrossRef
13.Nijsten TEC, Meuleman L, Lambert J. Chronic pruritic neutrophilic eccrine hidradenitis in a patient with Behçet’s disease. Br J Dermatol. 2002;147:797–800.CrossRef PubMed
14.Rouanet I, Jantac M, Lechiche C, Hope-Rapp E, Sotto A. Neutrophilic eccrine hidradenitis in an HIV-1-infected patient. AIDS. 2012;26:775–6.CrossRef PubMed
15.Dasanu CA, Bockorny B. Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported? J Oncol Pharm Pract. 2015;21:377–9.CrossRef PubMed
16.Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies. J Am Acad Dermatol. 2015;72:203–18.CrossRef PubMed
17.Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. JCO. Am Soc Clin Oncol. 2015;33:JCO.2013.52.9651–900.
18.Lilly E, Burke M, Kluger H, Choi J. Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib. JAMA Dermatol Am Med Assoc. 2015;151:102–3.CrossRef
19.Chaveli-López B. Oral toxicity produced by chemotherapy: a systematic review. J Clin Exp Dent Medicina Oral SL. 2014;6:e81–90.CrossRef
20.McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2001;9:283–9.CrossRef PubMed
21.Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P, Tosti A. Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol. 2011;33:345–50.CrossRef PubMed
22.Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A. Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol. 2011;64(3):604–6. doi:10.​1016/​j.​jaad.​2010.​03.​020 .
23.•
Shin H, Jo SJ, Kim DH, Kwon O, Myung SK. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis. Int J Cancer. 2015;136:E442–54. This paper is a meta-analysis of studies evaluating efficacy of prevention strategies for chemotherapy-induced alopecia.CrossRef PubMed
24.•
Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16:e181–9. Comprehensive review of chemotherapeutic effects on nail phenotypes.CrossRef PubMed
25.Capriotti K, Capriotti JA, Lessin S, Wu S, Goldfarb S, Belum VR, et al. The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol. 2015;173:842–5.CrossRef PubMed
26.Scotté F, Tourani J-M, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. JCO. 2005;23:4424–9.CrossRef
27.Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol Oxford University Press. 2005;16:1425–33.CrossRef
28.Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology Karger Publishers. 2007;72:152–9.
29.Chiang HC, Palamaras I. Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions. J Am Acad Dermatol. 2013;69(4):657–8. doi:10.​1016/​j.​jaad.​2013.​05.​032 .
30.Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Am Assoc Cancer Res. 2007;13:3913–21.
31.Yu J, Jin F, Zhu H, Kong L. A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review. OTT Dove Press. 2015;8:943–6.
32.Araki K, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, et al. Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. Breast Cancer Res Treat Springer US. 2014;148:197–209.CrossRef
33.Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, et al. Vemurafenib and radiosensitization. JAMA Dermatol Am Med Assoc. 2013;149:855–7.CrossRef
34.Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol Blackwell Publishing Ltd. 2012;167:1153–60.CrossRef
35.Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: survivors’ perspectives. Support Care Cancer Springer-Verlag. 2009;18:1461–8.CrossRef
36.Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer Nature Publishing Group. 2006;6:803–12.CrossRef
37.Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol Proc Am Soc Clin Oncol. 2009;27:1675–84.CrossRef
38.••Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol Elsevier. 2014;71:1102–1109.e1. Comparison of cutaneous side effects of BRAF inhibitors without and with MAP kinase inhibitors, including the decreased risk of cutaneous skin cancers in the latter group.CrossRef
39.Carrera C, Puig-Butillè JA, Tell-Marti G, García A, Badenas C, Alós L, et al. Multiple BRAF wild-type melanomas during dabrafenib treatment for metastatic BRAF-mutant melanoma. JAMA Dermatol. 2015;151:544–8.CrossRef PubMed
40.Chambers CJ, Liu H, White CR, White KP, Sharon VR. Eruptive purpuric papules on the arms; a case of chemotherapy-induced inflammation of actinic keratoses and review of the literature. Dermatol Online J. 2014;20(1):21246
41.Ali FR, Yiu ZZN, Fitzgerald D. Inflammation of actinic keratoses during paclitaxel chemotherapy. BMJ Case Rep. BMJ Publishing Group Ltd; 2015;2015:bcr2015209925–5.
42.Le Nouail P, Viseux V, Chaby G, Billet A, Denoeux JP, Lok C. DRESS (Drug reaction with eosinophilia and systemic symptoms) après traitement par imatinib (Glivec). Ann Dermatol Venereol. 2006;133:686–8.CrossRef PubMed
43.Valks R, Fraga J, Muñoz E, Bartolomé B, García-Díez A, Fernández-Herrera J. Acute generalized exanthematous pustulosis in patients receiving high-dose chemotherapy. Arch Dermatol Am Med Assoc. 1999;135:1418–20.CrossRef
44.Bracke A, Van Marck E, Lambert J. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction. Clin Exp Dermatol. 2009;34:337–9.CrossRef PubMed
45.Schwarz M, Kreuzer K-A, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002;69:254–6.CrossRef PubMed
46.Wu J, Lee YY, Su SC, Wu TS, Kao KC, Huang CC, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br J Dermatol. 2015:n/a–n/a.
47.Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet’s syndrome and associated-malignancy: a review of the current literature. Int J Oncol Spandidos Publications. 2013;42:1516–22.
48.Kyllo RL, Parker MK, Rosman I, Musiek AC. Ipilimumab-associated sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol. 2014;70:e85–6.CrossRef PubMed
49.Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for Imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354:2623–4.CrossRef PubMed
50.Ugurel S, Lahaye T, Hildenbrand R, Glorer E, Reiter A, Hochhaus A, et al. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. Br J Dermatol. 2003;149:678–9.CrossRef PubMed
51.Jagdeo J, Campbell R, Long T, Muglia J, Telang G, Robinson-Bostom L. Sweet’s syndrome–like neutrophilic lobular panniculitis associated with all-trans-retinoic acid chemotherapy in a patient with acute promyelocytic leukemia. J Am Acad Dermatol. 2007;56:690–3.CrossRef PubMed
52.Zimmer L, Livingstone E, Hillen U, Ömkes SD, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol Am Med Assoc. 2012;148:357–61.CrossRef
53.Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol Am Med Assoc. 2013;149:1071–5.CrossRef
54.Reinholz M, Berking C, Hermans C, Ruzicka T, Braun-Falco M. Lupus erythematosus–like skin eruption after vemurafenib therapy. J Am Acad Dermatol Elsevier. 2014;71:e159–60.CrossRef
55.Evans KG, Heymann WR. Paraneoplastic subacute cutaneous lupus erythematosus: an underrecognized entity. Cutis. 2013;91:25–9.PubMed
56.Inaoki M, Kawabata C, Nishijima C, Yoshio N, Kita T. Case of bleomycin‐induced scleroderma. J Dermatol Blackwell Publishing Ltd. 2012;39:482–4.CrossRef
57.Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999;112:456–62.CrossRef PubMed
  • 作者单位：Jennifer Gill (1)
    Arturo R. Dominguez (1)

    1. Department of Dermatology, University of Texas Southwestern, 5939 Harry Hines Blvd #300, Dallas, TX, 75235, USA
  • 刊物主题：Dermatology; Medicine/Public Health, general;
  • 出版者：Springer US
  • ISSN：2162-4933
    • 文摘
    Chemotherapy is well known to both clinicians and patients for its ability to cause unwanted adverse effects. The skin is an organ commonly affected by treatment with chemotherapy, leading to presentations ranging from mild to life-threatening. Recognition of these cutaneous effects is important as they impact morbidity and mortality as well as patient compliance. This review aims to discuss several of the most common cutaneous side effects of chemotherapies as well as recommendations for their diagnosis and management.

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700